Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?

The majority of breast cancers are hormone receptor positive due to the expression of the estrogen and/or progesterone receptors. Endocrine therapy is a major treatment option for all disease stages of hormone receptor–positive breast cancer and improves overall survival. However, endocrine therapy...

Full description

Saved in:
Bibliographic Details
Main Authors: Florian Reinhardt, André Franken, Tanja Fehm, Hans Neubauer
Format: Article
Language:English
Published: SAGE Publishing 2017-11-01
Series:Tumor Biology
Online Access:https://doi.org/10.1177/1010428317731511
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849248006076891136
author Florian Reinhardt
André Franken
Tanja Fehm
Hans Neubauer
author_facet Florian Reinhardt
André Franken
Tanja Fehm
Hans Neubauer
author_sort Florian Reinhardt
collection DOAJ
description The majority of breast cancers are hormone receptor positive due to the expression of the estrogen and/or progesterone receptors. Endocrine therapy is a major treatment option for all disease stages of hormone receptor–positive breast cancer and improves overall survival. However, endocrine therapy is limited by de novo and acquired resistance. Several factors have been proposed for endocrine therapy failures, which include molecular alterations in the estrogen receptor pathway, altered expression of cell-cycle regulators, autophagy, and epithelial-to-mesenchymal transition as a consequence of tumor progression and selection pressure. It is essential to reveal and monitor intra- and intertumoral alterations in breast cancer to allow optimal therapy outcome. Endocrine therapy navigation by molecular profiling of tissue biopsies is the current gold standard but limited in many reasons. “Liquid biopsies” such as circulating-tumor cells and circulating-tumor DNA offer hope to fill that gap in allowing non-invasive serial assessment of biomarkers predicting success of endocrine therapy regimen. In this context, this review will provide an overview on inter- and intratumoral heterogeneity of endocrine resistance mechanisms and discuss the potential role of “liquid biopsies” as navigators to personalize treatment methods and prevent endocrine treatment resistance in breast cancer.
format Article
id doaj-art-e04303f530e541acbbedf64715bc0c75
institution Kabale University
issn 1423-0380
language English
publishDate 2017-11-01
publisher SAGE Publishing
record_format Article
series Tumor Biology
spelling doaj-art-e04303f530e541acbbedf64715bc0c752025-08-20T03:58:04ZengSAGE PublishingTumor Biology1423-03802017-11-013910.1177/1010428317731511Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?Florian ReinhardtAndré FrankenTanja FehmHans NeubauerThe majority of breast cancers are hormone receptor positive due to the expression of the estrogen and/or progesterone receptors. Endocrine therapy is a major treatment option for all disease stages of hormone receptor–positive breast cancer and improves overall survival. However, endocrine therapy is limited by de novo and acquired resistance. Several factors have been proposed for endocrine therapy failures, which include molecular alterations in the estrogen receptor pathway, altered expression of cell-cycle regulators, autophagy, and epithelial-to-mesenchymal transition as a consequence of tumor progression and selection pressure. It is essential to reveal and monitor intra- and intertumoral alterations in breast cancer to allow optimal therapy outcome. Endocrine therapy navigation by molecular profiling of tissue biopsies is the current gold standard but limited in many reasons. “Liquid biopsies” such as circulating-tumor cells and circulating-tumor DNA offer hope to fill that gap in allowing non-invasive serial assessment of biomarkers predicting success of endocrine therapy regimen. In this context, this review will provide an overview on inter- and intratumoral heterogeneity of endocrine resistance mechanisms and discuss the potential role of “liquid biopsies” as navigators to personalize treatment methods and prevent endocrine treatment resistance in breast cancer.https://doi.org/10.1177/1010428317731511
spellingShingle Florian Reinhardt
André Franken
Tanja Fehm
Hans Neubauer
Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?
Tumor Biology
title Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?
title_full Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?
title_fullStr Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?
title_full_unstemmed Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?
title_short Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?
title_sort navigation through inter and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer a potential role for liquid biopsies
url https://doi.org/10.1177/1010428317731511
work_keys_str_mv AT florianreinhardt navigationthroughinterandintratumoralheterogeneityofendocrineresistancemechanismsinbreastcancerapotentialroleforliquidbiopsies
AT andrefranken navigationthroughinterandintratumoralheterogeneityofendocrineresistancemechanismsinbreastcancerapotentialroleforliquidbiopsies
AT tanjafehm navigationthroughinterandintratumoralheterogeneityofendocrineresistancemechanismsinbreastcancerapotentialroleforliquidbiopsies
AT hansneubauer navigationthroughinterandintratumoralheterogeneityofendocrineresistancemechanismsinbreastcancerapotentialroleforliquidbiopsies